Melanotan-1 is FDA-approved. Not as an injection, and not for tanning.

Why this note exists

"FDA-approved" is the single most load-bearing phrase in peptide marketing, and Melanotan-1 is a case where it is literally true and almost entirely beside the point. The approval is narrow, the product form is unusual, and the endpoint the approval rests on measures something no cosmetic buyer is trying to achieve.

In the index generated on August 14, 2026, 54 of 112 vendors carried a Melanotan-1 listing — 62 listings, twenty-fourth of 83 compounds by vendor coverage.[24] One of those 62 listings uses the name afamelanotide anywhere in the product title and none mention Scenesse; the rest sell it as Melanotan-1, Melanotan I or MT-1.[24] Where a size is stated, 10 mg is overwhelmingly the common vial: 43 of the 62.[24] Melanotan II, a different peptide, is carried by 86 vendors and ranks thirteenth.[25]

A note on what kind of evidence this is: every efficacy and safety figure below is human data, carrying its design and participant count. One paragraph reports animal and in vitro toxicology and is labeled as such. Case reports are called case reports in the same sentence as their finding, and pepmg does not convert a labeled dose into a protocol for a research vial.

The approval

What FDA approved, in FDA's words

The indication is one sentence, and every qualifier in it is doing work: Scenesse "is indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP)."[1] EPP is an inherited deficiency of ferrochelatase; protoporphyrin IX accumulates and reacts with light, and FDA's review describes phototoxicity as "the main clinical feature of EPP, which leads to intense pain with sun exposure," with no FDA-approved products for the condition at the time of review.[3]

The dosage form is the part that never survives the trip to a product page. The label describes "a single, solid white to off-white, bioresorbable and sterile rod approximately 1.7 cm in length and 1.45 mm in diameter," containing 16 mg of afamelanotide in a poly(DL-lactide-co-glycolide) copolymer, stored refrigerated, inserted subcutaneously 3–4 cm above the anterior supra-iliac crest with a dedicated cannula, every two months, by a healthcare professional who "should be proficient in the subcutaneous implantation procedure and ha[s] completed training prior to administration."[1] The label instructs that the patient be monitored for 30 minutes afterwards, and notes the implant "may not be able to be located from 10 days after insertion" if it needs to come out.[1]

Two procedural facts belong here, both from the approval letter. The application was dated November 8, 2018 and carried a major amendment in May 2019 that extended the goal date by three months.[2] And FDA states plainly that "[y]our application for Scenesse was not referred to an FDA advisory committee because the application did not raise significant safety or efficacy issues in the intended population."[2] The pediatric assessment normally required under PREA did not apply because the product holds an orphan designation — in the letter's words, "you are exempt from this requirement" — which is why the label still says safety and effectiveness "have not been established in pediatric patients."[1][2]

Europe got there first and hedged harder. The European Commission granted a marketing authorisation on 22 December 2014 for the prevention of phototoxicity in adults with EPP — and EMA records that "[t]his medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use."[6]

The pivotal evidence

Three trials, 244 adults, and a p-value of 0.055

The efficacy package is three vehicle-controlled randomized trials in adults with EPP, enrolling 244 subjects in total, of whom 125 received afamelanotide and 119 received vehicle implants.[1][3] The trial population was 98% Caucasian with a mean age of 40.[1] Two of the three were designed around pain-free sun exposure.

Enrollment and results as tabulated in the prescribing information and FDA's multi-disciplinary review. The third trial, CUV030, is counted in the pooled safety population; FDA's review states its prespecified endpoints did not reach statistical significance.[1][3]

FDA's own executive summary is unusually explicit about how close the main result was. It states that the applicant submitted "one adequate and well-controlled trial (Study CUV039)," that for that trial "the p-value for the primary endpoint was close to the statistical significance level of 0.05," that the sponsor's analysis excluding subjects with no post-baseline efficacy data "calculated a p-value of 0.044," and that "[a]n analysis that includes all randomized subjects with imputation for missing data conducted by FDA has a p-value of 0.055."[3] On CUV029 the review says afamelanotide was statistically superior to vehicle (p=0.005) for the pain-free sun endpoint, while noting the study "had some data quality issues"; on CUV030 it says the trial "did not demonstrate statistical significance on the prespecified endpoints based on the severity of phototoxic reactions," and that the pain-free sun endpoint there was defined post hoc and "thus cannot be relied on to support efficacy."[3]

The peer-reviewed report of the two sun-exposure trials, published in The New England Journal of Medicine in 2015, describes the same two studies — 74 patients in the European Union, 94 in the United States, randomized 1:1 to implants every 60 days — and reports the US result as a median 69.4 pain-free hours versus 40.8 (P=0.04) and the EU result as 6.0 versus 0.8 hours (P=0.005), with fewer phototoxic reactions in the EU study (77 vs 146, P=0.04).[5] The trials were funded by Clinuvel and others, which the authors disclose.[5] Where the label's figures differ slightly from the journal's, that is FDA's analysis of the same trials rather than a second experiment.[1][5]

Read the endpoint before you read the effect

The number that matters most in this file is 6.0 versus 0.75 hours — and it is a measure of disability, not of pigmentation. In CUV029, the primary endpoint was "the total number of hours over 270 days spent outdoors between 10 am and 3 pm on days with no pain for which 'most of the day' was spent in direct sunlight," and the label notes that this analysis "does not include sun exposure on days for which subjects reported spending time in a combination of both direct sunlight and shade."[1] Nine months of daily diaries, a five-hour window, one restrictive category — and the median patient on placebo logged forty-five minutes across the whole study.

That is the honest scale of EPP. It is also the reason the result is meaningful to the people in the trial and says nothing whatsoever about a healthy adult's tan. The endpoint counts hours a person could be outdoors without severe pain. It does not measure melanin density, cosmetic outcome, sun protection in normal skin, or anything that would transfer to someone without a ferrochelatase deficiency.

Uncontrolled real-world data since approval point the same direction on the same question. An Austrian cohort published in 2026 reported on all 20 Austrian EPP patients treated in 2023: median phototoxic burn tolerance time rose from 15 minutes to 250 minutes, median EPP quality-of-life score from 11.11 to 79.17, and the share of patients experiencing phototoxic reactions fell from 88% to 33%, with side effects described as mild and transient.[15] Twenty patients, no control group, before-and-after comparison — supportive of the approved use, and not evidence about anything else.[15]

The gap

Nobody has run the study the market is implicitly citing

There is no controlled trial of afamelanotide taken chronically by healthy people for cosmetic pigmentation. The human data in healthy volunteers are small pharmacology studies. The label's pharmacokinetics come from 12 healthy adults given a single implant, with high variability and a mean C_max of 3.7 ± 1.3 ng/mL and an apparent half-life of about 15 hours.[1] The registry lists a completed phase 1 study of 10 healthy volunteers with skin types I–III examining ultraviolet-induced DNA damage and repair capacity — single-group, open-label, no comparator.[11]

Across the whole registry, a ClinicalTrials.gov search on August 15, 2026 returned 23 registered studies of afamelanotide — 22 interventional and one observational — spanning EPP, vitiligo, xeroderma pigmentosum, polymorphic light eruption, solar urticaria, variegate porphyria, acne, actinic keratoses and ischemic stroke.[12] Several of those are 3-to-6-patient pilots. The compound has one approved indication.[4]

The one large study still running is in vitiligo, and it is worth describing precisely because its result will be quoted. CUV105 is a phase 3 comparison of Scenesse plus narrow-band UVB against narrow-band UVB alone, with an estimated enrollment of 200 and a primary outcome of "[p]ercentage of patients achieving T-VASI 50 on the body" from baseline to day 140.[10] Its registry record lists allocation as randomized and masking as none — an open-label trial with a visually assessed pigmentation endpoint.[10] The sponsor announced full recruitment of 200 patients in May 2025 and said first results from the study were expected in the second half of 2026; nothing has been reported as of August 15, 2026.[13][10]

Safety

What the label records, and the study FDA ordered because the label could not settle it

In the pooled safety population of 244 adults, the adverse reactions occurring in more than 2% of subjects were led by implant site reactions (21% vs 10% on vehicle), nausea (19% vs 14%), oropharyngeal pain (7% vs 5%), cough (6% vs 3%), fatigue (6% vs 3%) and skin hyperpigmentation (4% vs 0%).[1] FDA's benefit-risk summary records no deaths in the safety population and serious adverse events in 4% on afamelanotide against 3% on vehicle.[3] Postmarketing, the label now carries hypersensitivity reactions "including urticaria, angioedema, and anaphylaxis," and a warning to that effect.[1]

The label also asks prescribers to watch the skin: Scenesse "[m]ay induce darkening of pre-existing nevi and ephelides due to its pharmacological effect. A full body skin examination (twice yearly) is recommended to monitor pre-existing nevi and new skin pigmentary lesions."[1]

Animal and in vitro data, labeled as such: the label states that "[c]arcinogenicity studies have not been conducted with SCENESSE," that afamelanotide was negative in the Ames test, an in vitro mouse lymphoma assay and an in vivo mouse bone marrow micronucleus assay, and that no effects on fertility or reproductive performance were seen in rats at subcutaneous doses up to 20 mg/kg/day, about 12 times the maximum recommended human dose on a body-surface-area basis.[1] None of that is a carcinogenicity study, and none of it is human data.

FDA's own view of that gap is in the approval letter, and it is the most useful sentence in this note. Under section 505(o) FDA determined that "an analysis of spontaneous postmarketing adverse events … will not be sufficient to identify an unexpected serious risk of skin cancer and implant site reactions," and required a "prospective, longitudinal, registry based observational exposure cohort study" following US EPP patients "for a minimum of eight years," with primary adverse events of interest listed as "skin cancer (melanomas and non-melanomas)" and administration-site reactions.[2]

A second postmarketing requirement, a thorough QT study, was scheduled in the letter for a final report in February 2022; the review notes QT evaluation "was not part of afamelanotide development program."[2][3] The honest reading of all of this: the approved product is well tolerated over the exposure that has been studied, and the long-term skin-cancer question was open enough in 2019 that FDA ordered an eight-year cohort to answer it, which is still running.[2]

The market

Two different peptides, one nickname, and a case-report literature that cannot tell them apart

Melanotan-1 and Melanotan II are not variants of one product. The Scenesse label gives afamelanotide's structure as a linear 13-amino-acid α-MSH analogue, Ac-Ser-Tyr-Ser-Nle-Glu-His-(D)Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂, molecular weight 1646.85.[1] Melanotan II is a different, cyclic melanocortin agonist and has no approval anywhere.[14] pepmg tracks them as separate compounds for that reason.[24][25]

The published harm literature is almost entirely case reports, and it usually records "melanotan" without saying which. The most careful review of it, in the International Journal of Dermatology in 2017, concluded that unregulated use of both melanotan I and II "is associated with cutaneous complications, particularly melanocytic changes in existing moles and newly emerging (dysplastic) nevi," that four case reports had then described melanomas emerging from existing moles during or shortly after melanotan use, and — the sentence that matters — that "conclusive evidence linking these phenomena is lacking."[14] It also notes that multiple national health organizations have issued safety warnings about both.[14]

That literature has continued to accumulate, still one patient at a time. Recent additions include five primary melanomas in situ in a patient with tanning-bed use, melanotan exposure and anabolic hormone use (2026); mucosal malignant melanoma of the anterior maxilla in a 22-year-old after Melanotan II nasal spray, reported as a "possible risk factor" (2025); pyoderma gangrenosum at melanotan injection sites, described by its authors as not previously reported (2025); oral mucosal pigmentation after 64 days of self-injected Melanotan II (2026); and depigmented facial and neck patches following melanotan use (2026).[18][19][21][22][23] Case reports establish that something happened in one person. They do not establish incidence, and they do not establish cause. A 2026 commentary in the same journal as the 2017 review frames the current pattern as unregulated melanotan use promoted via social media, with dermatologic and public-health risk.[20]

The other half of the mismatch is the product itself. The approved article is a refrigerated, sterile, controlled-release implant with a defined release profile, placed by a trained clinician.[1] What 54 vendors list is a lyophilized powder in a 10 mg vial for reconstitution.[24] Those are different pharmaceutical products with the same active peptide named on them, and pepmg makes no claim about the contents of any vendor's vial.

Where the field is going, briefly

Afamelanotide's position in EPP is being contested on the merits, which is a healthy sign and a source of the next round of headlines. A 2026 review notes that afamelanotide "is the only approved treatment for EPP" and "is currently only approved for use in adult patients, leaving children and adolescents without a treatment option," and covers two investigational alternatives, dersimelagon and bitopertin, whose trial data "suggests treatment effects in EPP as compared to placebo control groups" while needing further characterization.[16] A 2025 analysis of the trial protocols by a patient organization found 29 registered EPP trials and argued that because of differing outcome measures and populations, "the results of the trials cannot be directly compared."[17] None of that changes what is approved today.

Three things this note is not saying

First, it is not saying the approval was wrong or thin in a way that should embarrass anyone. EPP is a lifelong, painful, ultra-rare disease that had no approved treatment; two randomized trials plus a supportive third, in a condition affecting roughly 1 in 75,000, is a serious evidence package for that setting, and FDA reviewers recorded a favorable benefit-risk conclusion.[3]

Second, it is not saying afamelanotide does not work. It has a well-characterized mechanism at the melanocortin 1 receptor, it increases eumelanin independently of UV exposure, and both randomized and real-world data in EPP point the same way on pain-free light exposure.[1][5][15]

Third, it is not saying melanotan causes melanoma. The published association is case reports and a review that explicitly declines to call it conclusive; the honest statement is that the long-term skin-cancer question is unresolved for the approved product too, which is exactly why FDA required an eight-year registry.[14][2]

What it is saying is narrower: "FDA-approved" is a true statement about Melanotan-1, and it means a 16 mg implant, placed by a clinician every two months, that lets adults with a rare porphyria spend measurably more hours outdoors without pain — approved on a primary endpoint that FDA's own imputation analysis put at p = 0.055.[1][3] Nothing in that sentence is about tanning.

Questions people are asking